- Home
- WRLD vs KROS Comparison
WRLD vs KROS Comparison
Compare WRLD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRLD | KROS |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.6M | 584.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WRLD | KROS |
|---|---|---|
| Price | $138.62 | $11.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 113.4K | ★ 387.1K |
| Earning Date | 04-27-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | ★ $564,841,465.00 | $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | ★ N/A | $4.87 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $104.99 | $9.12 |
| 52 Week High | $185.48 | $22.55 |
Technical Indicators
Market Signals| Indicator | WRLD | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 20.45 |
| Support Level | $138.35 | N/A |
| Resistance Level | $140.69 | $15.21 |
| Average True Range (ATR) | 7.29 | 0.69 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 53.93 | 14.44 |
Price Performance
Historical ComparisonAbout WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.